Intelerad Acquires PenRad Technologies
What You Should Know: – Today, Intelerad, a leading global provider of enterprise medical imaging solutions, announced its acquisition of PenRad, a software provider for […]
What You Should Know: – Today, Intelerad, a leading global provider of enterprise medical imaging solutions, announced its acquisition of PenRad, a software provider for […]
Merck & Co has ramped up its involvement in the RNA category, partnering with US biotech Orna Therapeutics in a deal valued at up to […]
On the same day as it reported encouraging new data for its cancer drug Trodelvy, Gilead Sciences has agreed a deal to buy rights to […]
The FDA has started a review of Roche’s Polivy for people with previously untreated diffuse large B-cell lymphoma (DLBCL), as the drugmaker tries to move […]
AstraZeneca and Merck & Co’s PARP inhibitor Lynparza is already used to treat prostate cancer associated with a specific genetic mutation, but could see its […]
In the space of a couple of months, Gilead Sciences’ Trodelvy impact on overall survival (OS) in the TROPICs-02 trial in advanced breast cancer has […]
The 3rd TIGIT Axis Therapies Summit returns to unite large pharma, innovative biotechs and pioneering academics to discuss the full range of next-generation TIGIT axis targeted […]
Novartis has secured its first approval in Europe for prostate cancer radioligand therapy Pluvicto, getting a green light from the UK Medicines and Healthcare products […]
Bristol-Myers Squibb is on course to move its BCMA-targeting CAR-T therapy further up the treatment pathway in multiple myeloma, after reporting that it met its […]
EGFR inhibitors like AstraZeneca’s Tagrisso have been hugely successful in treating EGFR-positive lung cancer, but the durability of treatment is often reduced by resistance mutations. […]
Magnetic resonance imaging (MRI) technology specialist Bot Image has won FDA approval for its artificial intelligence-powered software ProstatID, used for the detection and diagnosis of […]
AI could address the most significant issue in drug discovery, finds Ben Hargreaves, and also offers the potential to use tissue samples to create precision […]
Bayer has won a key FDA approval to extend the use of its prostate cancer therapy Nubeqa, as it tries to claim market share from […]
The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu as the first targeted therapy for HER2-low breast cancer, a new category of the disease that […]
David Talby, CTO, John Snow Labs Digital twins are virtual representations of an object or system that spans its lifecycle, is updated from real-time data, […]
What You Should Know: – Xenex Disinfection Services has announced the 5-year renewal of its U.S. General Services Administration (GSA) contract, which enables federal agencies […]
Sanofi is making a €300 million investment in Chinese biotech Innovent as part of a collaboration to bring two new cancer therapies as quickly as […]
Unlocking the secrets of the human genome has long been an ambitious pursuit for researchers around the world. Over the past two decades, innovative research […]
The European Commission has cleared AstraZeneca and Merck & Co’s Lynparza as an adjuvant or neoadjuvant treatment for breast cancer, extending its lead over would-be […]
Two phase 3 trials of Merck & Co’s Keytruda in metastatic castration-resistant prostate cancer (CRPC) and advanced liver cancer have ended in failure, proving once […]
What You Should Know: – Annexus Health, Inc. has announced its Series B financing of $33 million, which was led by leading digital health growth […]
Roche has announced a pair of licensing deals with Poseida Therapeutics and Kiniksa Pharmaceuticals that bolster its pipeline in cancer and inflammatory diseases. The agreement […]
Ipsen and Servier’s hopes of extending the uses for chemotherapy drug Onivyde have been knocked back by a failed phase 3 trial of the drug […]
Gilead Sciences’ investment in oncology has started to provide a solid return, with sales of cancer therapies breaching the $500 million threshold for the first […]
Bristol-Myers Squibb has revealed that its checkpoint inhibitor combination of Opdivo and Yervoy failed a phase 3 trial as adjuvant (post-surgery) therapy for renal cell […]
AstraZeneca chief executive Pascal Soriot said this morning that strong revenue increases in 2022 – fuelled by its COVID-19 antibody Evusheld and oncology drugs – […]
Bristol-Myers Squibb’s new immune checkpoint inhibitor combination Opdualag has only been on the US market for a few weeks, but is already off to a […]
For years, the promise of therapeutic cancer vaccines has intrigued researchers working in the oncology space. And for good reason. The concept of pre-emptively training […]
Newly diagnosed cancer patients across the UK will get free access to digital mental health therapies, thanks to a new partnership between Macmillan Cancer Support […]
AstraZeneca and Daiichi Sankyo will hear back from the FDA before the end of 2022 on their license application for Enhertu in HER2-low breast cancer […]
Roche has been trumpeting the rapid uptake of its new eye disease drug Vabysmo as it takes on Regeneron and Bayer’s mighty Eylea in the […]
The EMA’s human medicines committee has recommended approval of Johnson & Johnson’s Tecvayli as a fourth-line therapy for multiple myeloma, joining a growing group of […]
Researchers at the University of Texas MD Anderson Cancer Center published a new study revealing that cancer cells make their own unique form of collagen […]
While immunotherapies have transformed treatment of many types of cancer, they do sometimes fail to have an impact – as Merck & Co has just […]
It has suspected for many years that some diseases may be linked to non-coding or ‘junk’ DNA, but the mechanism behind the pathology hasn’t been […]
Cancer Research UK has expanded an alliance with investment group Deep Science Ventures with a commitment to support the formation up to 10 new oncology […]
AstraZeneca and Merck’s PARP inhibitor Lynparza has carved out blockbuster revenues across uses in breast, ovarian, prostate and pancreatic cancer, but colorectal cancer won’t be […]
China’s Simcere Pharmaceutical has been granted approval in its home market for Cosela, a drug designed to limit the side effects of cancer chemotherapy partnered […]
AstraZeneca and Daiichi Sankyo have claimed approval in the EU for Enhertu as a second-line therapy for HER2-positive metastatic breast cancer, moving the drug up […]
Byondis has filed its HER2-targeting antibody-drug conjugate (ADC) trastuzumab duocarmazine in the US and Europe, setting up possible approvals next year and a showdown with […]
Illumina’s attempt to prevent the European Commission from carrying out an antitrust review of its $8 billion takeover last year of cancer diagnosis firm Grail […]
Pfizer’s tyrosine kinase inhibitor Xalkori has picked up a fourth approval from the FDA, adding a new use in the treatment of a rare form […]
Cost-effectiveness watchdog NICE has recommended routine NHS use of two new therapies for women with advanced breast cancer – Gilead’s Trodelvy and Novartis’ Piqray – […]
An EU-funded project that aims to encourage the implementation of artificial intelligence-based personalised care for lung cancer patients – dubbed I3LUNG – has formally launched. […]
As they seek to support their staff, self-insured employers are turning to innovative programs to balance evidence based programs with the need to manage healthcare […]
Merck & Co has added another clinical-stage drug to its oncology pipeline via a licensing agreement with Finland’s Orion for ODM-208, a prostate cancer candidate […]
Roche’s Genentech unit has gone all in on its collaboration with UK biotech Bicycle Therapeutics, taking up an option on a second additional target in […]
What You Should Know: – RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT) for all stages of cancer, today announced […]
Swedish rare disease specialist Sobi is paying $55 million upfront to license rights to ADC Therapeutics’ lymphoma therapy Zynlonta – approved in the US last […]
Noel Alaka, VP of Life Sciences at COTA What You Should Know: Today, oncology real-world data analytics company COTA announced the appointment of Noel Alaka as Vice President of […]
The rumour that Merck & Co is preparing to make a sizeable offer to buy cancer specialist Seagen won’t go away. The latest report – […]
Eradicating cancer is an ambitious goal for oncologists and life science companies around the world. But, with a growing number of cancer treatments entering the […]
The FDA has granted a priority review to Roche’s T-cell engager Lunsumio as a treatment for follicular lymphoma (FL), setting up a decision on the […]
The FDA approves new cancer treatments in half the time of the EMA – but does faster mean better? And how can regulators balance timely […]
AstraZeneca has signed a deal to buy US biotech TeneoTwo in a deal worth up to $1.27 billion that will boost its position therapies for […]
Cancer drugs will be flown from a facility in Portsmouth to a hospital on the Isle of Wight by drone, in the first pilot study […]
Novartis is still waiting for FDA approval of its PD-1/PD-L1 inhibitor latecomer tislelizumab in relapsed oesophageal cancer, but is already planning a move the drug […]
Just weeks after Bristol-Myers Squibb claimed an FDA green light for Opdivo as a neoadjuvant therapy for non-small cell lung cancer, AstraZeneca is looking to […]
Blueprint Medicines has taken an unusual route to raising cash for its R&D pipeline – selling off some of the royalties from its already-approved medicines […]
A Swiss newspaper has said Novartis’ previously announced restructuring programme could lead to 8,000 axed jobs, including up to 1,400 at its home base in […]
Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to be dosed every six months – after […]
SAE Media Group is delighted to announce the 2nd Annual Conference Oligonucleotide Therapeutics & Delivery, taking place on the 21st and 22nd September 2022 in […]
Astellas has agreed a $1.36 billion partnership with US biotech Sutro Biopharma for a series of antibody-drug conjugates for cancer, focusing on applications in patients […]
The revamp of French drugmaker Ipsen has continued with a takeover agreement for US counterpart Epizyme and its cancer therapy Tazverik, in a deal valued […]
Alex Adjei MD, PhD, will serve as the new chair of Cleveland Clinic’s Taussig Cancer Institute starting in July, the system said June 23.
Alex Adjei MD, PhD, will serve as the new chair of Cleveland Clinic’s Taussig Cancer Institute starting in July, the system said June 23.
Nashville, Tenn.-based HCA Healthcare inked a deal with McKesson June 23 to enter a joint venture combining the two institutions’ cancer research efforts.
Novartis’ two-drug regimen of Tafinlar and Mekinist has been approved by the FDA as the first therapy for solid tumours that have a BRAF V600E […]
The University of Texas MD Anderson Cancer Center, Invectys and the Cell Therapy Manufacturing Center entered a strategic collaboration last week to develop a “reliable, […]
The University of Texas MD Anderson Cancer Center, Invectys and the Cell Therapy Manufacturing Center entered a strategic collaboration last week to develop a “reliable, […]
Cleveland Clinic Mercy Hospital is in the early stages of developing a $10.3 million cancer center, The Repository reported June 20.
Scottsdale, Ariz.-based HonorHealth researchers developed a novel drug combination therapy for pancreatic cancer patients that has become part of the new National Comprehensive Cancer Network […]
Speculation that Merck & Co may be preparing a $30 billion takeover bid for Seagen – bolstering its oncology ambitions – has the biopharma community […]
Thousands more people with breast cancer in England look set to be eligible for routine treatment with Eli Lilly’s Verzenios, after new guidance from NICE […]
A personalised, treatment plan for patients with breast cancer is the first digital health product to emerge from a newly-announced partnership between digital health specialist […]
MorphoSys seemingly inexorable shift into an oncology pure-play has continued with an out-licensing deal for two programmes in the kidney disease and immunology categories to […]
Six hospitals and health systems that have opened specialty cancer facilities or shared plans to open new centers since April:
Fargo, N.D.-based Sanford Roger Maris Cancer Center launched its new bone marrow transplant program June 14, KFGO reported.
Houston-based University of Texas MD Anderson Cancer Center will establish the Andrew M. McDougall Brain Metastasis Clinic and Research Program after a $5 million gift […]
Boehringer Ingelheim must like what it has seen in its two-year-old R&D collaboration with Trutino Biosciences to develop cytokine therapies – it has just taken […]
The 2nd NSCLC Drug Development Summit returns for its second year to unite biopharma and academic leaders during an exciting era of personalized medicine. The industry is uniting to address […]
Richmond, Va.-based VCU Health began offering free breast and cervical cancer screening services to low-income and uninsured women in Virginia through a federally funded program […]
Grand Rapids-based Cancer and Hematology Centers of Western Michigan and OneOncology, a national platform for independent oncology practices, entered a partnership to expand the center’s […]
ADC Therapeutics is looking to add a second approved antibody-drug conjugate to its portfolio after reporting strong phase 2 results with camidanlumab tesirine (cami) in […]
Three years after Daiichi Sankyo’s FLR3 inhibitor quizartinib was rejected by the FDA, the drugmaker has reported the results of a new phase 3 trial […]
Boston-based Dana-Farber Cancer Institute signed a cooperation agreement with L’Institut Servier and Gustave Roussy in Villejuif, France, on June 7.
The CDC awarded $215 million in first-year funding June 8 to three national programs as part of a five-year, $1.1 billion investment in preventing and […]
Here are five recent cancer study findings:
While Merck & Co’s Keytruda is the undisputed leader of the non-small cell lung cancer (NSCLC) category, there’s one category where it lags behind Roche’s […]
Eric Winer, MD, director of New Haven, Conn.-based Yale Cancer Center and physician-in-chief of Smilow Cancer Network, began a one-year term as president of the […]
Eric Winer, MD, director of New Haven, Conn.-based Yale Cancer Center and physician-in-chief of Smilow Cancer Network, began a one-year term as president of the […]
Miami Beach, Fla.-based Mount Sinai Medical Center named Steven Hochwald, MD, the inaugural director of Mount Sinai’s new Irma and Norman Braman Cancer Center on […]
Adult childhood cancer survivors are 80 percent more likely to be undertreated for cardiovascular disease risk factors, a study published June 8 in the Journal […]
Roche has secured its first regulatory approval for mosunetuzumab, a first-in-class CD20xCD3 bispecific antibody, as a treatment for patients with follicular lymphoma (FL) in the […]
Combination therapies are fast becoming the cornerstone of cancer treatment: not just in the UK, but across the world. With strong evidence to support how […]
Each year across Europe, 3.7 million people are diagnosed with a form of cancer, resulting in 1.9 million deaths, making cancer the second largest cause […]
Eisai’s first-ever attempt at developing an antibody-drug conjugate for cancer was rewarded with a $3.1 billion licensing deal from Bristol-Myers Squibb, and new data reported […]
Obese adults who achieved weight loss from bariatric surgery were associated with a 32 percent lower risk of developing cancer, a June 3 study from […]
Breast cancer and cervical cancer screenings dropped during the first year of the COVID-19 pandemic, a survey published June 3 in JAMA Network Open found.
Every rectal cancer patient in a small trial taking dostarlimab, or checkpoint inhibitors, saw remission, The New York Times reported June 5.
Johnson & Johnson and Pfizer both highlighted new data with BCMA-targeting bispecific antibodies in patients with relapsed or refractory multiple myeloma (RRMM) at ASCO, previewing […]
In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast cancer, and, at ASCO, they finally revealed […]
In March, Gilead Sciences reported positive results for its TROPiCS-02 study of Trodelvy, but the guarded tone of the announcement led to speculation that the […]
Bristol-Myers Squibb’s all-cash offer for Turning Point Therapeutics – which values the biotech at $4.1 billion – bolsters its position in precision oncology and gives […]
Six hospitals and health systems that have opened new cancer facilities or shared plans to open new centers since May:
Here are the top 10 oncology stories Becker’s covered in May:
For the first time since 2019, the American Society of Clinical Oncology (ASCO) annual meeting will be an in-person conference. We’re excited to re-connect with […]
Medical imaging specialist Median Technologies has launched a new business unit that will provide decision-making tools – underpinned by artificial intelligence – for sponsors of […]
Astellas has become the latest big pharma company to sink some money into immuno-oncology start-up GO Therapeutics, forging an alliance to develop antibodies targeting two […]
To improve outcomes for cancer patients and take advantage of the ground-breaking scientific and technological progress made in oncology prevention, diagnosis, therapy and care over […]
The U.S. only has slightly better-than-average cancer mortality rates than other high-income countries despite spending twice as much on associated care, a study published May […]
The FDA expanded its approval for CAR-T therapy in treating cancer patients with relapsed or refractory follicular lymphoma after two or more lines of systemic […]
The US Securities and Exchange Commission has sued a former AstraZeneca executive over alleged insider trading in connection with its 2019 deal to acquire rights […]
For decades, RAS has existed as an elusive therapeutic target, and drugging this high-value oncogene was deemed impossible. Despite this, the first-ever FDA-approved KRAS G12C inhibitor has […]
Shares in Swedish biotech RhoVac were down 94% in mid-morning trading today after the company revealed a phase 2b trial of its prostate cancer vaccine […]
The American Society of Clinical Oncology, or ASCO, conference is just around the corner, but one subgroup of cancer researchers just had their own gathering, […]
The FDA has cleared two combination drug regimens based on Bristol-Myers Squibb’s PD-1 inhibitor Opdivo for previously-untreated advanced oesophageal cancer, encroaching on territory held by […]
The 13th Annual World Multispecific Summit will deliver a greater scope and penetration of innovative technical content than any other meeting. This year’s re-imagined agenda will cover unique target discovery, mechanistic […]
Accelerating the Discovery, Translation & Large-Scale Manufacturing of Exosomes & EVs With 3 days of unrivaled content and two dedicated tracks, this year’s summit will be […]
Mirati Therapeutics will hear from the FDA on its KRAS inhibitor adagrasib later this year, hoping to compete with first-to-market rival Lumakras from Amgen. However, […]
Roche will present the new data at next week’s ASCO congress showing that its bispecific antibody glofitamab can achieve high and durable responses in patients […]
Johnson & Johnson and Legend Biotech will arrive at next week’s ASCO congress with a new EU approval for multiple myeloma CAR-T Carvykti. The European […]
The UC Davis Comprehensive Cancer Center named Xiao-Jing Wang, MD, PhD, its new chief scientific officer, the center said in a May 26 email to […]
Cleveland-based University Hospitals Seidman Cancer Center appointed Koen van Besien, MD, PhD, to lead its division of hematology and as director of the Wesley Center […]
The co-founder of Los Angeles biotech Enochian Biosciences has been arrested in connection with a federal investigation into the murder of a Vermont man in […]
Servier is on course to get a return on its $1.8 billion takeover of Agios Pharma’s oncology business after getting a key FDA approval for […]
After more than six years of development, Angle has scored an FDA approval for Parsortix as a diagnostic for metastatic breast cancer – the first […]
Around 100 patients in England and Wales with triple negative breast cancer (TNBC) that has spread to other parts of the body could soon access […]
Philadelphia-based Penn Medicine and Children’s Hospital of Philadelphia are partnering with Costa Rica’s Caja Costarricense de Seguro Social (Social Security Program), to facilitate CAR-T research […]
Sarasota (Fla.) Memorial Hospital’s new $220 million cancer pavilion was approved by the county’s public hospital board, The Sarasota Herald-Tribune reported May 23.
Seven oncologists joined new practices or received new appointments in the last few weeks.
What You Should Know: – Tempus, an $8B precision medicine company, announced the launch of a new psychiatric real-world data program to leverage real-world data to inform […]
In February, Atara Biotherapeutics paused enrolment into a trial of a CAR-T cell therapy for mesothelioma after a patient death. Now, its partner Bayer has […]
Several of the top pharmaceutical companies have joined a new coalition that aims to improve access to cancer medicines in low- and lower-middle-income countries (LLMICs). […]
The inaugural Targeted Radiopharmaceuticals Summit US will bring together a worldwide community of specialists to address long-standing challenges in radiopharmaceutical development at all stages, from bench to […]
What You Should Know: – Cerner, Elligo Health Research® and Freenome are collaborating to enable a clinical trial through the Learning Health Network to help advance early cancer detection. – Together they […]
HealthQuest Capital Team What You Should Know: – HealthQuest Capital, a sector specialist capital firm focused on companies optimizing value in healthcare, today announced the […]
Pittsburgh-based UPMC Hillman Cancer Center opened its first location in Sicily at UPMC-managed ISMETT, a “leading transplant and high-specialty” hospital in Palermo.
Pittsburgh-based UPMC Hillman Cancer Center opened its first location in Sicily at UPMC-managed ISMETT, a “leading transplant and high-specialty” hospital in Palermo.
Merck & Co has quietly added another drug to its immuno-oncology pipeline via an agreement with China’s Sichuan Kelun Pharmaceutical, and is keeping the details […]
Madison, Wis.-based UW Health, the integrated health system of the University of Wisconsin-Madison, is beginning construction on the first center in the world to offer […]
Cleveland Clinic Cancer Center has initiated a drug repository program providing orally administered drugs used in cancer treatment at no charge to eligible patients.
Arlington Heights, Ill.-based Northwest Community Healthcare has proposed construction of a $86.8 million cancer treatment center, The Daily Herald reported May 18.
Women with breast cancer in England and Wales will soon be able to access a new diagnostic based on an injectable magnetic marker liquid called […]
Here are five recent cancer center firsts Becker’s has covered since March 21:
Milwaukee-based Froedtert and the Medical College of Wisconsin are planning to offer proton therapy for cancer patients requiring radiation therapy, The Milwaukee Journal Sentinel reported […]
AstraZeneca has boosted its research capacity by extending its oncology partnership with Proteros biostructures. German pharma firm Proteros specialises in structure-based drug discovery powered by […]
Simon Mathews, MD, Chief Medical Officer, Pager Digital health companies (DHCs) and their solutions continue to grow at a rapid pace. This is in part […]
iTeos Therapeutics has said it is evaluating with partner GlaxoSmithKline whether to conduct additional clinical trials of TIGIT drug EOS-448 following the failure of a […]
Bristol-Myers Squibb’s flurry of dealmaking has continued with en expansion of its partnership with BridgeBio on drugs targeting SHP2, in the hope of combining them […]
Charlottesville, Va.-based UVA Health and the Focused Ultrasound Foundation have launched the world’s first cancer center focused on enhancing the effectiveness of immunotherapy treatment by combining […]
Roche’s anti-TIGIT antibody tiragolumab has failed a second phase 3 trial, dousing expectations for the programme and its hopes of finding a companion to its […]
What You Should Know: – OncoHost, an AI-powered precision oncology platform, today announced a $35M Series C funding round led by ALIVE Israel HealthTech VC, […]
Roche has elevated a longstanding alliance with Finland’s Kaiku Health focusing on digital patient monitoring and management (DPMM) to the level of a strategic partnership. […]
Here are six recent cancer study findings:
Adding Nykode Therapeutics’ VB10.16 vaccine to treatment with Roche’s cancer immunotherapy Tecentriq resulted in disease control in two-thirds of patients with advanced cervical cancer. The […]
A study has shown that a mobile game can be used to gather symptom data from children undergoing treatment for cancer, and potentially might also […]
Novartis has shut down production of its radioligand therapies – one of its key growth areas – at facilities in Europe and the US after […]
New York Cancer & Blood Specialists partnered with Episcopal Health Services, the parent company of New York City-based St. John’s Episcopal Hospital, to build a […]
The FDA has kicked off a priority review of AstraZeneca’s checkpoint inhibitor Imfinzi for biliary tract cancer (BTC), setting up what could be approval for […]
Novartis’ CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences’ […]
With TCEs being studied in both hematological and solid tumors (39 and 34 trials respectively), there are now more than one hundred projects in the preclinical […]
Israeli cancer diagnosis startup Imagene AI has raised $21.5 million in first-round financing for its cancer diagnosis platform based digitised imaging of biopsy samples. The […]
Gilead Sciences has made another foray into the natural killer (NK) cell category, paying $300 million upfront to access Dragonfly Therapeutics’ TriNKET platform to find […]
Here are the top 10 oncology stories Becker’s covered in April:
The FDA has declined to approve two more cancer therapies developed by drugmakers based in China, in what may be further evidence of a tough […]
What You Should Know: – Kelonia Therapeutics, a Boston-based biotech company focused on vivo gene delivery, launched with a $50 million in Series A funding […]
Here are eight moves from leading cancer centers across the nation that Becker’s has covered since March 28:
An artificial intelligence-powered digital tool for diagnosing skin cancers developed by Skin Analytics has been cleared in the UK as a Class IIA medical device, […]
The University of Texas MD Anderson Cancer Center and Indianapolis-based Community Health Network entered a partnership April 28 to create Community Health Network MD Anderson […]
The University of Texas MD Anderson Cancer Center and Indianapolis-based Community Health Network entered a partnership April 28 to create Community Health Network MD Anderson […]
Kentucky has the highest cancer death rate per 100,000 in the U.S., according to a new analysis from the Kaiser Family Foundation.
Tampa, Fla.-based Moffitt Cancer Center researchers developed a radiomic model to predict patients who may experience poor lung cancer outcomes.
AstraZeneca and Daiichi Sankyo have claimed a fifth breakthrough designation from the FDA for Enhertu, shortly after the showing the drug extended survival in patients […]
Here are five hospitals and health systems that have opened new cancer facilities or shared plans to open new centers since April 12:
San Francisco-based Blumio and Saint Paul, Minnesota-based NxGenPort tied for the top prize in the Remote Patient Monitoring and Smart Devices track of INVEST Pitch […]
Nektar has said it will cut 70% of its workforce in the wake of the comprehensive failure in trials of its immuno-oncology candidate bempegaldesleukin, which […]
Compared to a ‘critical organ’ that had been largely ignored, companies working to develop microbiome-based therapies believe there is untapped potential in the area. Ben […]
Shares in Nkarta more than doubled yesterday on the results of early-stage clinical that suggested it could be on to a winner with its natural […]
With the undeniable excitement in the BCMA field over the past few months, the BCMA Targeted Therapies Summit returns to the space to equip you […]
CAR-T therapies have revolutionised the treatment of some blood cancers, but are costly as well as time- and resource-intensive. Now, US researchers think one solution […]
Here are five recent moves announced by the American Cancer Society since March 31:
AstraZeneca’s anti-CTLA4 antibody tremelimumab is moving closer to what once looked like an extremely unlikely regulatory approval, after a string of negative trial results. The […]
Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears […]
Are you using TCRs to target solid tumors yet? With Immunocore having achieved commercialization for the first TCR therapy in both the US and EU […]
Roche is on the brink of its first regulatory approval for what could be the first bispecific antibody targeting CD3 and CD20 – mosunetuzumab – […]
What You Should Know: – Mayo Clinic has signed a research agreement with VUNO, a global medical artificial intelligence (AI) company to develop advanced AI-driven […]
Six oncologists joined new practices or received new appointments in the last few weeks.
A study involving data from more than 25,000 cancer survivors found those who reported medical financial hardships had a higher mortality risk than those without […]
It’s estimated that humans create a combined 2.5 quintillion bytes of data each day – and that around 90% of all data to ever exist was created […]
Break Through Cancer, a research foundation, has awarded $50 million to five of the nation’s leading cancer centers to spearhead projects aimed at improving outcomes […]
The potential of CRISPR technology has been a hot topic in the industry ever since it was first developed, but as trials progress further into […]
SMi Group Reports: The leading Pain Therapeutics Conference will take place for its 22nd consecutive year on 4th and 5th May 2022 in London, UK […]
Regeneron has agreed an all-cash deal to acquire CheckMate Pharmaceuticals, adding immune activator vidutolimod to its cancer immunotherapy pipeline and ending a barren spell for […]
What You Should Know: – Transcarent, a new, different, and better health and care experience company for employees of self-insured employers and their families launches […]
William Dahut, MD, has been named chief scientific officer for the American Cancer Society. He will start May 16.
AstraZeneca and Daiichi Sankyo should only have to wait for six months to hear from the FDA if it will approve their HER2 drug Enhertu […]
It has long been understood that the Hippo pathway plays a critical role in the development of a wide range of diseases. Although once seen […]
Four years after Bristol-Myers Squibb paid $1.85 billion upfront to make Nektar’s bempegaldesleukin a companion drug to its cancer immunotherapy Opdivo, the alliance is being […]
St. Jude Children’s Research Hospital named J. Paul Taylor, MD, PhD, scientific director and executive vice president, it said in an email to Becker’s April […]
The University of Texas MD Anderson Cancer Center named Eileen Danaher Hacker, PhD, the chair of its nursing department, it said in an email to […]
Here are four cancer-related partnerships formed or expanded since April 1, starting with the most recent:
Penn Medicine appointed Robert Vonderheide, MD, to a second five-year term as director of its Abramson Cancer Center, it said April 13.
Oligonucleotide Therapeutics and Delivery Conference 2022 Date: 21st – 22nd September 2022 Location: London, UK Website: www.oligonucleotide.co.uk/pharmaphorum Advancements in extra-hepatic delivery of oligonucleotides The Oligonucleotide […]
Two years after signing a $3.9 billion alliance with Genmab to find new cancer therapies, AbbVie has said it is ready to start talking to […]
The massive backlog in patient care across Europe resulting from the pandemic will take at least three years to clear and in some cases as […]
Penn Medicine has appointed Robert Vonderheide, MD, to a second five-year term as director of the Abramson Cancer Center at the University of Pennsylvania in […]
AbbVie’s BCL-2 inhibitor navitoclax has reported phase 2 results in a trial involving rare and hard-to-treat blood cancer myelofibrosis, eyeing an indication not addressed with […]
GlaxoSmithKline has agreed a deal to buy Sierra Oncology and its lead drug momelotinib for anaemia associated with the blood cancer myelofibrosis, sending the US […]
Boston-based Dana-Farber Cancer Institute named Ian Matthew-Clayton vice president and chief inclusion, diversity and equity officer, effective April 25.
Gilead Sciences can restart pivotal trials of its cancer antibody magrolimab – the centre piece of its $4.9 billion acquisition of Forty Seven in 2020 […]
Novartis has joined the select cadre of drugmakers developing KRAS inhibitors for cancer, opening its account with phase 1b data on JDQ443 showing efficacy in […]
Physicians at Boston-based Dana-Farber Cancer Institute are witnessing the consequences of delayed cancer screenings, which are still down from pre-pandemic levels, Bloomberg reported April 11.
Physicians at Boston-based Dana-Farber Cancer Institute are witnessing the consequences of delayed cancer screenings, which are still down from pre-pandemic levels, Bloomberg reported April 11.
Hackensack (N.J.) Meridian John Theurer Cancer Center is expanding its services to Jersey Shore University Medical Center in Neptune City, N.J., it said in an […]
Hackensack (N.J.) Meridian John Theurer Cancer Center is expanding its services to Jersey Shore University Medical Center in Neptune City, N.J., it said in an […]
Here are five hospitals and health systems that have opened new cancer facilities or shared plans to open new centers since March 10:
Houston Methodist Willowbrook became the first hospital in the area to perform a transurethral ultrasound ablation, an advanced treatment for prostate cancer, the Houston Chronicle […]
Affimed says new data from a phase 1/2 trial of its natural killer (NK) cell engager therapy AFM13 provide further evidence of its efficacy in […]
Adding an mRNA vaccine to CAR-T cell therapy could be the key to unlocking activity in solid tumours, according to German biotech BioNTech. CAR-Ts have […]
What You Should Know: – PathAI and GSK announced a multi-year strategic artificial intelligence (AI) partnership today with a focus on accelerating research and- building drug development programs […]
Jazz Pharma has bolstered its pipeline of cancer drugs through a $1.3 billion licensing agreement with Werewolf Therapeutics that adds its first immuno-oncology candidate. The […]
The EU regulator has started a review of Novartis’ PD-1 inhibitor tislelizumab – licensed from Chinese biotech BeiGene – for oesophageal and lung cancers, ahead of […]
Parliamentarians in the UK have warned that the government is not making the effort needed to reach its target of diagnosing three quarters of cancer […]
Boehringer Ingelheim says it is planning to invest a hefty €25 billion ($27 billion) in its pipeline over the next five years, as it reinvests […]
Immunocore now has approval on both side of the Atlantic for Kimmtrak – the first cancer therapeutic based on T cell receptor (TCR) technology – […]
Researchers at the Institute of Cancer Research (ICR) in London have designed a prototype test that they think could be used to predict which combinations […]
Seattle-based Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle Children’s and UW Medicine have restructured their long-standing partnership and formed a unified adult […]
The following oncologists joined new practices or organizations in the last few weeks:
News about an entire North Carolina cancer center board resigning in light of the director’s removal was Becker’s most read oncology story in March.
Novartis chief executive Vas Narasimhan, already eyeing a possible divestment of generics business Sandoz, has now turned his attention to the rest of the company. […]
Gilead Sciences’ Kite Pharma has become the first drugmaker to get FDA approval to use a CAR-T therapy after just one earlier systemic therapy, moving […]
Dorothy Graves, PhD, has joined the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine as assistant vice president and associate director […]
Bronx, N.Y.-based Albert Einstein Cancer Center made three new leadership appointments March 29.
Bronx, N.Y.-based Albert Einstein Cancer Center made three new leadership appointments March 29.
Roche has suffered a setback with its much-anticipated pairing of anti-TIGIT antibody tiragolumab and PD-L1 inhibitor Tecentriq in small cell lung cancer (SCLC), in a […]
Sanofi has agreed another deal to flesh out its R&D pipeline, paying IGM Biosciences $150 million upfront to gain access to its engineered IgM antibody […]
What You Should Know: – ConcertAI, LLC (ConcertAI), the leader in enterprise AI and real-world data (RWD) solutions for life sciences and healthcare, announced the […]
Tens of millions of dollars have been donated to fund specialty cancer centers and accelerate cancer research in recent weeks.
The Children’s Hospital of Philadelphia has received a “significant” gift from Susan and Steve Kelly to establish a center for cancer immunotherapy, the hospital said […]
The University of Texas MD Anderson Cancer Center launched an immunotherapy research institute with James Allison, PhD, as its inaugural director.
Roche has moved a step closer to extending the use of its B-cell lymphoma therapy Polivy into the first-line setting, after getting a recommendation for […]
Johnson & Johnson is in course for approval of its multiple myeloma CAR-T therapy Carvykti in the EU the next few weeks, after getting a […]
MEI Pharma and partner Kyowa Kirin have had to abandon plans to file for approval of their PI3K inhibitor zandelisib in B cell lymphoma, after […]
AstraZeneca’s hopes of developing its PD-L1 inhibitor Imfinzi for cervical cancer have been hit by a failed phase 3 trial of the drug alongside chemotherapy […]
Geisinger held a ribbon cutting March 23 on an $80 million expansion to the cancer center at Geisinger Wyoming Valley Medical Center in Wilkes-Barre, Pa.
Miruna Sasu, Ph.D., MBA, President & CEO at COTA, Inc. What You Should Know: – COTA, Inc., an oncology real-world data and analytics company, announced […]
Adam Marko, Director of Life Science Solutions at Panasas The healthcare industry is experiencing a data deluge, and it shows no sign of slowing down. […]
Novartis has been steadily investing in radiopharmaceuticals over the last few years, and one of those deals has just paid off with an FDA approval […]
Here are three findings made by Yale Cancer Center scientists Becker’s has covered since March 4:
Copyright © 2024 | WordPress Theme by MH Themes